Last reviewed · How we verify
Enstilar® foam
Enstilar foam combines a potent corticosteroid (betamethasone dipropionate) with a vitamin D analog (calcipotriene) to reduce inflammation and normalize skin cell differentiation in psoriasis.
Enstilar foam combines a potent corticosteroid (betamethasone dipropionate) with a vitamin D analog (calcipotriene) to reduce inflammation and normalize skin cell differentiation in psoriasis. Used for Plaque psoriasis in adults.
At a glance
| Generic name | Enstilar® foam |
|---|---|
| Also known as | Enstilar 0.005%-0.064% Topical Foam, calcipotriene and betamethasone dipropionate |
| Sponsor | Icahn School of Medicine at Mount Sinai |
| Drug class | Topical corticosteroid + vitamin D analog combination |
| Target | Glucocorticoid receptor; vitamin D receptor (VDR) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Betamethasone dipropionate acts as a glucocorticoid receptor agonist, suppressing inflammatory cytokines and immune cell infiltration in the skin. Calcipotriene is a vitamin D3 analog that promotes keratinocyte differentiation and reduces proliferation. Together, they provide complementary anti-inflammatory and anti-proliferative effects with potentially improved efficacy and safety compared to corticosteroid monotherapy.
Approved indications
- Plaque psoriasis in adults
Common side effects
- Application site irritation
- Skin atrophy
- Folliculitis
- Pruritus
Key clinical trials
- Residual Disease MEMory in PSOriasis Skin During EnstiLAR® and Narrow-band Ultraviolet B Therapy: The MEMPSOLAR Study (PHASE4)
- Efficacy and Safety of LEO 90100 Foam in Japanese Subjects With Psoriasis Vulgaris (PHASE3)
- Assessing the Efficacy of Image-guided Laser-assisted Enstilar® Delivery for Treatment of Psoriatic Nails (PHASE2)
- Observational Study in Patients With Nail Psoriasis Treated With Enstilar® to Assess the Severity Change and the Quality of Life
- PSOREAL - Managing PSOriasis in the REAL World
- Enstilar® Foam in the Treatment of Chronic Plaque Psoriasis in Patients With Skin of Color (PHASE4)
- To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064%, in the Treatment of Psoriasis Vulgaris (Plaque Psoriasis). (PHASE3)
- Efficacy and Tolerability of Enstilar® in Daily Practice
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Enstilar® foam CI brief — competitive landscape report
- Enstilar® foam updates RSS · CI watch RSS
- Icahn School of Medicine at Mount Sinai portfolio CI